Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 151 Breast Neoplasms 116 Carcinoma, Non-Small-Cell Lung 65 Triple Negative Breast Neoplasms 45 Neoplasms 44 Neoplasm Metastasis 44 Lung Neoplasms 26 Ovarian Neoplasms 25 Squamous Cell Carcinoma of Head and Neck 24 Stomach Neoplasms 22 Melanoma 16 Esophageal Neoplasms 16 Adenocarcinoma 15 Head and Neck Neoplasms 13 Recurrence 12 Esophageal Squamous Cell Carcinoma 12 Cholangiocarcinoma 12 Sarcoma 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 11 Small Cell Lung Carcinoma 10 Fallopian Tube Neoplasms 10 Uterine Cervical Neoplasms 9 Urinary Bladder Neoplasms 8 Pancreatic Adenocarcinoma 8 Colorectal Neoplasms 8 Prostatic Neoplasms 7 Inflammatory Breast Neoplasms 7 Carcinoma, Pancreatic Ductal 7 Breast Neoplasms, Male 7 Biliary Tract Neoplasms 7

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Albumin-Bound Paclitaxel × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡